Biotechnology company United Therapeutics Corporation (Nasdaq: UTHR) on Wednesday announced full enrollment for the TETON 2 study, which evaluates Tyvaso (treprostinil) inhalation solution for treating idiopathic pulmonary fibrosis (IPF). The study, part of the global TETON clinical trial program, enrolled 597 patients and targets top-line data release in the second half of 2025.

The TETON program includes three studies: TETON 1 in the US and Canada, TETON 2 outside North America and TETON PPF, which focuses on progressive pulmonary fibrosis (PPF). These studies build on data from the INCREASE study, which demonstrated significant improvements in forced vital capacity (FVC) for IPF patients using Tyvaso.

Tyvaso's integration in these studies aims to offer a new treatment avenue for IPF and PPF patients, who currently have limited options. United Therapeutics plans to seek FDA approval to expand Tyvaso's label to include IPF and PPF following the TETON studies.

United Therapeutics, a public benefit corporation, continues to innovate in the biotech field, focusing on unmet medical needs and expanding the availability of transplantable organs.